HPHela-Felicitas Petereit

Hela-Felicitas Petereit

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hela-Felicitas Petereit has a total of 43 co-authors. Here are the top co-authors by number of shared publications:

  • R Pukrop

    Department of Neurology and Psychiatry, University of Cologne, Josef-Stelzmann-Str. 9, 50924 Köln, Germany

    3 shared publications
  • Dirk Reske

    Department of Neurology, University of Cologne, Cologne, Germany

    2 shared publications
  • G Japp

    Department for Neurology and Rehabilitation, Alt Falkenstein 2, 61426 Königstein, Germany

    2 shared publications
  • S Merkelbach

    Department of Neurology, University of Homburg/Saar, Kirrbergstraße, 66421 Homburg/Saar, Germany

    2 shared publications
  • S Schoppe

    Department of Neurology, University of Cologne, D-50924 Cologne, Germany

    2 shared publications
  • W D Heiss

    Department of Neurology and Psychiatry, University of Cologne, Josef-Stelzmann-Str. 9, 50924 Köln, Germany

    2 shared publications

Latest Publications

  • Fatale familiäre Insomnie

    by A. V. Thomas, J. C. Klein, A. Brockhaus-Dumke, W. D. Heiss, A. H. Jacobs, H. F. Petereit

    Die fatale familiäre Insomnie (FFI) ist eine vererbbare Prionenerkrankung, die durch eine Mutation im Codon 178 des Prionproteingens (PRNP) auf Chromosom 20 verursacht wird. Die Erkrankung ist durch gestörten Nachtschlaf und hieraus resultierende Vigilanzstörungen sowie eine Vielzahl weiterer neurologischer Symptome gekennzeichnet. In dieser Arbeit werden anhand einer Kasuistik die typischen klinischen und bildgebenden Befunde diskutiert. Im vorliegenden Fall konnte die Diagnose erst post mortem gesichert werden, nachdem ein immunsuppressiver Behandlungsversuch unter der klinischen Verdachtsdiagnose einer zerebralen Vaskulitis das Fortschreiten der Erkrankung nicht verhindern konnte. Insbesondere wird erläutert, inwiefern moderne Diagnosemethoden wie die Positronenemissionstomographie PET mit [15O]H2O und [18F]FDG sowie die Single-Photon-Emissions-Computertomographie (SPECT) eine sinnvolle Ergänzung zu konventionellen bildgebenden Methoden und der genetischen Testung darstellen. Fatal familial insomnia (FFI) is a hereditary prion disease caused by a mutation in codon 178 of the prion protein gene PRNP on chromosome 20. It is characterized by disturbed night sleep, resulting in daily vigilance perturbations and a variety of other neurological symptoms. We present the case of a 46-year-old woman deteriorating despite immunosuppressive treatment which was initiated suspecting cerebral vasculitis as the cause of her progressive neurological symptoms. The correct diagnosis was established only post mortem. Based on the case presented here, we discuss typical clinical symptoms and imaging findings. In particular, we outline how modern diagnostic methods such as positron emission tomography with [15O]H2O and [18F]FDG and single photon emission computed tomography can add valuable information to results from conventionally performed imaging techniques and genetic testing.


  • Liquoranalytik in der Diagnostik erregerbedingter Erkrankungen des Zentralnervensystems

    by H.-F. Petereit, H. Seifert, H. K. Geiss, B. Wildemann


  • No effect of intravenous immunoglobulins on cytokine-producing lymphocytes in secondary progressive multiple sclerosis

    by H F Petereit, D Reske, R Pukrop, M Maas-Enriquez, G Japp, P Jh Jongen, H W Kölmel, S Merkelbach, H P Hartung, W D Heiss, et al.

    Intravenous immunoglobulins (IVIG) have been effective in reducing multiple sclerosis (MS) disease activity and improving disability scores. However, the mechanism by which this beneficial effect is achieved remains unclear. An effect of IVIG on pro- and anti-inflammatory cytokines- which are thought to play a role in the disease process- has been postulated in a number of animal and ex vivo studies. Hence, we performed a study on 34 patients with secondary progressive (SP) MS being treated with monthly IVIG or placebo for two years according to the protocol of the ESIMS study. Clinical outcome measures and cytokine production (interferon gamma, tumour necrosis factor alpha, interleukin-4 and -10) were recorded in all patients and compared with respect to the treatment group. Against our expectations, IVIG did not reduce the relapse rate or the progression of disability or cytokine production. Our data argue against an enduring immunomodulating effect of IVIG, at least in SPMS.


  • Zerebrale zystische Echinokokkose

    by D. Reske, H.-F. Petereit, M. Neveling, W.-D. Heiss

    Berichtet wird der Fall eines 35-jährigen Patienten aus Mitteleuropa, der an einer histologisch gesicherten zystischen Echinokokkose der Leber erkrankt ist. Als Grunderkrankung besteht bei dem Patienten eine Infektion mit dem human immunodeficiency virus. Der Patient wurde durch einen ersten Grand-Mal-Anfall neurologisch auffällig. In der weiterführenden Diagnostik ließ sich die Diagnose einer zerebralen zystischen Echinokokkose stellen. Der mögliche Zusammenhang der zerebralen zystischen Echinokokkose mit der HIV-Erkrankung wird hier diskutiert. Die zystische zerebrale Echinokokkose ist eine seltene zerebrale Komplikation der zystischen Echinokokkose, die anhand dieses Fallberichtes und einer kurzen Übersicht der aktuellen Literatur dargestellt werden soll. In diesem Fall scheint der ursächliche Zusammenhang der zerebralen Aussaat der Zysten mit der Immunsuppression wahrscheinlich. We report on a HIV-positive 35-year old patient who suffered from a cystic echinococcosis of the liver. The diagnosis was established by microbiological tests of the liver. Furthermore, the patient suffered from seizures leading to the diagnosis of a cerebral cystic echinococcosis. The underlying HIV-disease and its role in the course of the cerebral echinococcosis is discussed. As the cerebral manifestation of a cystic echinococcosis is rare, especially in Central Europe, we discuss the case report and give a short review of the literature. In this case, the cerebral manifestation of the echinococcosis with the immunosuppression caused by HIV seems to be probable.

  • Open Access

    Expansion of antibody reactivity in the cerebrospinal fluid of multiple sclerosis patients – follow-up and clinical implications

    by Hela-Felicitas Petereit, Dirk Reske

    Background: An intrathecal polyspecific antibody response is a well known finding in multiple sclerosis. However, little is known about the evolution of intrathecal antibodies over time and their impact on the disease progress. Therefore, we focused in this study on the intrathecal polyspecific antibody response in multiple sclerosis. Methods: Here we present a follow-up study of 70 patients with multiple sclerosis over 1 to 106 months. Serum and cerebrospinal fluid sample pairs were obtained from 1 to 5 consecutive lumbar punctures. CSF cell count, the IgG index, local IgG synthesis, oligoclonal bands and the antibody index for measles, rubella or varicella zoster were calculated. Results were analysed with regard to clinical characteristics of the patients. Results: Once an intrathecal antibody response was established, it persisted. De novo antibody response against measles virus developed in 7% of the patients between the first and the second spinal tap. In two of seven patients where 5 consecutive CSF samples were available, the intrathecal antibody response expanded from one to three antigens. Furthermore, an intrathecal measles antibody production was associated with a rapid progression of the disease. Conclusion: These data stress the importance of activated B cells for the disease process and the clinical outcome in multiple sclerosis.


  • Low interleukin-10 production is associated with higher disability and MRI lesion load in secondary progressive multiple sclerosis

    by H.F Petereit, R Pukrop, F Fazekas, S.U Bamborschke, S Röpele, H.W Kölmel, S Merkelbach, G Japp, P.J.H Jongen, H.P Hartung, et al.


  • Effect of immunomodulatory drugs on in vitro production of brain-derived neurotrophic factor

    by H F Petereit, H Lindemann, S Schoppe

    Multiple sclerosis (MS), a disease of presumably autoimmune aetiology, is character ized by inflammation, demyelination and axonal degeneratio n in the central nervous system. C urrent treatment concepts target the inflammatory activity, reducing the number of relapses and inflammatory lesions on magnetic resonance imaging as well as the proinflammatory cytokine production in blood lymphocytes. Recently, the neuroprotective aspect of inflammation has been documented and is thought to be mediated by neurotrophins, like brain-derived neurotrophic factor (BDNF). The question whether the in vitro BDNF production in MS patients and healthy controls is influenced by the immunomodulatory agents interferon beta (IFN-beta) and immunoglobulin G (Ig) is addressed. A significantly increased BDNF production in MS patients was found compared with normal controls (mean±SD: 492±172 pg/mL versus 217±55 pg/mL, P-0.001). IFN-beta and low-dose Ig had no effect on BDNF production, whereas high-dose Ig reduced in vitro BDNF production in MS patients significantly (to 409±125 pg/mL, P-0.001). These in vitro findings might indicate that Igs in high doses potentially interfere with neuroprotective mechanisms despite their potent anti-inflammatory properties.


  • Low interferon gamma producers are better treatment responders: a two-year follow-up of interferon beta-treated multiple sclerosis patients

    by H F Petereit, S Nolden, S Schoppe, S Bamborschke, R Pukrop, W D Heiss

    As response to interferon beta (IFNB) treatment, a 50% reduction of the mean relapse rate compared to pretreatment values has been reported. However, individual responses vary considerably, ranging from no reduction in exacerbation frequency to complete suppression of relapses for at least two years. At the moment, valid predictors for IFNB response are lacking. Here we present a prospective evaluation of 33 patients with primary relapsing multiple sclerosis, who were followed for two years of IFNB treatment. A low interferon gamma (IFG) production before treatment predicted a two-year term without exacerbations in 68.8% of cases correctly, whereas a high pretreatment IFG production implied the risk of at least one relapse in the first two years in 70.6%. These preliminary results encourage further evaluation of IFG as predictor of an IFNB treatment response.


    • 1 August 2002
      • Vol. 73  (8)

    [DRGs as future reimbursement system for hospital services exemplified by multiple sclerosis].

    by H F Petereit, G Ruffing, F X Weilbach, N Zessack, U K Zettl


  • Die DRGs als zukünftiges Abrechnungssystem der Krankenhausleistungen am Beispiel der Multiplen Sklerose

    by H. F. Petereit, G. Ruffing, F. X. Weilbach, N. Zessack, U. K. Zettl

    Die Einführung des pauschalierten Entgeltsystems auf der Basis der “Diagnosis Related Groups” (DRG) wird weitreichende Konsequenzen für die ambulante und stationäre Versorgung der Patienten in Deutschland haben. Dies gilt insbesondere für die Indikationsstellung zur stationären Therapie, aber auch für den Leistungsumfang und die Liegezeit. Auch die Multiple Sklerose als häufigste entzündliche Erkrankung des Nervensystems in Europa mit Jahreskosten von 2,3 Mrd. Euro allein in Deutschland wird hiervon betroffen sein. Beispielhaft soll für dieses Krankheitsbild aufgezeigt werden, wie vollständiges Kodieren sich auf das Entgelt auswirkt, wobei Übersichtstabellen zu praktisch relevanten Nebendiagnosen und Komplikationen bereit gestellt werden. Gleichzeitig werden das gesundheitspolitische Potenzial des neuen Entgeltsystems als Steuerungs- und Qualitätssicherungsinstrument sowie seine Schwächen, sogar potenzielle Risiken für die Patientenversorgung bei fehlenden Leitlinien für Diagnostik und Therapie exemplarisch diskutiert.